Bio-TechneMEX:TECH 83 Return-on-Tangible-Equity is 27.54% as of Mar. 2026, which is 60% below its 10-year median of 69.34. GuruFocus rates MEX:TECH with a GF Score™ of 83/100 and a GF Value™ of MXN1,115.93. The stock has 8 warning signs investors should review. Among 1,199 Biotechnology companies, Bio-Techne ranks better than 89.99% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bio-Techne's annualized net income for the quarter that ended in Mar. 2026 was MXN3,682 Mil. Bio-Techne's average shareholder tangible equity for the quarter that ended in Mar. 2026 was MXN13,370 Mil. Therefore, Bio-Techne's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 27.54%.
The historical rank and industry rank for Bio-Techne's Return-on-Tangible-Equity or its related term are showing as below:
MEX:TECH'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 12.64 Med: 69.34 Max: 269.65
Current: 16.61
During the past 13 years, Bio-Techne's highest Return-on-Tangible-Equity was 269.65%. The lowest was 12.64%. And the median was 69.34%.
MEX:TECH's Return-on-Tangible-Equity is ranked better than 89.99% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs MEX:TECH: 16.61
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bio-Techne Return-on-Tangible-Equity Related Terms
Bio-Techne Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bio-Techne's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TECH vs ARWR, CYTK, KRYS: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Bio-Techne's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 27.54% mean?
Bio-Techne (MEX:TECH) has a Return-on-Tangible-Equity of 27.54% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bio-Techne and its competitors. This is 60% below median its historical median of 69.34. Over the past decade, Bio-Techne's Return-on-Tangible-Equity has ranged from 12.64 to 269.65. According to the industry distribution chart, Bio-Techne ranks #120 out of 1199 companies in the Biotechnology industry, placing it in the top 10%.
Is Bio-Techne's Return-on-Tangible-Equity too high?
Bio-Techne's current Return-on-Tangible-Equity of 27.54% is 60% below median its 10-year median of 69.34. Over the past 10 years, this metric has ranged from a low of 12.64 to a high of 269.65. Based on the distribution chart, Bio-Techne ranks #120 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Techne has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Return-on-Tangible-Equity compare to ARWR and CYTK?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #120 out of 1199 companies for Return-on-Tangible-Equity. This places Bio-Techne in the top 10% of its industry — outperforming the majority of peers. Historically, Bio-Techne's own Return-on-Tangible-Equity has ranged from 12.64 to 269.65 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bio-Techne and its competitors. Bio-Techne's current Return-on-Tangible-Equity is 27.54%, which is 60% below median its own 10-year median of 69.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Bio-Techne (MEX:TECH) has a current Return-on-Tangible-Equity of 27.54%. The stock's GF Value™ is MXN1,115.93, compared to a current price of MXN1,090.00 — trading 2.3% below its estimated fair value. The current Return-on-Tangible-Equity is 27.54%, which is 60% below median its 10-year median of 69.34. Bio-Techne's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bio-Techne (MEX:TECH), the current Return-on-Tangible-Equity is 27.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (MEX:TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued.
The current stock price of MXN1,090.00 is trading 2.3% below its estimated GF Value™ of MXN1,115.93.
Key valuation signals for MEX:TECH:
Return-on-Tangible-Equity: 27.54% (60% below median its 10-year median of 69.34)
GF Value™: MXN1,115.93 vs. price of MXN1,090.00 (2.3% below fair value)
No single metric tells the full story. See the MEX:TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
83GF Score
Get the complete analysis for MEX:TECH
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TECH has been successfully added to your 
